Search NWBO
NORTHWEST BIOTHERAPEUTICS INC
OTC · CIK 1072379
Last close0.15
Daily change+0.00 (0.00%)
10 Years gain-70.59%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NWBO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
28.0Momentum
100.0Acceleration
100.0Confidence
71.0Annual Revenue16
Quarterly Revenue55
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth6.0 / 25
Quality6.8 / 25
Capital Efficiency13.8 / 20
Balance Sheet0.1 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1459.5109 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 20.8123%.
Key Metrics
Revenue Growth TTM10.79%OK
Revenue CAGR 3Y-6.45%OK
Gross Marginn/aMISSING
Operating Margin-3,162.01%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y20.81%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.38M | n/a | -$59.91M | -$44.76M | -$46.27M | n/a | -4,347.9% | -3,357.55% | n/a | 1.46B |
| 2025 FY Dec 31, 2024 | $1.38M | n/a | -$66.51M | -$57.02M | -$58.03M | n/a | -4,812.45% | -4,199.06% | n/a | 1.24B |
| 2024 FY Dec 31, 2023 | $1.93M | n/a | -$55.51M | -$53.64M | n/a | n/a | -2,873.08% | n/a | n/a | 1.12M |
| 2023 FY Dec 31, 2022 | $1.68M | n/a | -$67.18M | -$52.78M | n/a | n/a | -3,991.74% | n/a | n/a | 1.02M |
| 2023 FY Dec 31, 2021 | $1.01M | n/a | -$52.70M | -$38.30M | n/a | n/a | -5,243.98% | n/a | n/a | 1.01M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.63M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-097188, 0001104659-25-112676 |
| Revenue Growth TTM | 10.79% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-097188, 0001104659-25-112676 |
| Revenue CAGR 3Y | -6.45% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-043806 |
| Revenue CAGR 5Y | 1.31% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-043806 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-097188, 0001104659-25-112676 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -3,162.01% | Operating Income / Revenue | OK | 0001104659-26-097188, 0001104659-25-112676 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-097188 |
| Current Ratio | 0.04x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.01x | (Cash + Short-term Investments) / Total Debt | OK | 0001104659-26-097188 |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001104659-26-097188, 0001104659-25-112676 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001104659-26-043806 |